Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The development of a new more efficient and easy to install high strength solar collector withstanding high temperature (120°)and operating pressures form circulating water and externals. (THERMOTEX)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Sweden,Czechia,Germany,United Kingdom,Belgium,Germany,Spain,Denmark,Portugal
Call:  (FP7-SME-2007-1, 2007)
Start date: 2008-10-01
End date: 2011-06-30
Duration (months): 33.0
Total project cost (EUR): 1054561.77
EU funding (EUR): 812943.0
Participants: 10
Project status: CLOSED

This project will target the fast growing market for solar collector systems. The competitiveness of the EU solar collector industry is a major issue in this rapidly increasing market. Currently, European industry is lagging behind the China and US, which exports solar collector components to the EU. Also competition will become increasingly intense, as new players from other low labour cost countries are now entering the market for collector systems. The proposed project will increase the competitiveness of the 6,000 SMEs in the European solar collector sector by providing them with a technology that will significantly improve the efficiency and cost effectiveness of collector modules. This will provide the sector with the necessary momentum to increase their competitiveness against current market leaders in China and the United States. Current solar collector module technologies are based on top plate absorber polymeric system. However, these systems have poor thermal conductivity, which lead to poor performance of the systems. We propose to overcome these problems by developing a more efficient, cost effective and easy to install polymeric solar collector module, with hybrid parallel plate back absorber and projection fins to increase the efficiency of the absorber thermal conductivity. The operating temperature is 120°C with high mechanical strength to withstand pressure from the circulating water and the external environment. We will support EU policy to reduce harmful CO2 emissions from fossil fuels and help reach the EU target of 320 Gigawatt (GWth) of solar thermal output by 2020. In addition, the proposal will help towards The European Union meeting its commitment to cut greenhouse gas emissions according to the Kyoto Protocol.

Keywords: solar collector
Enhancing the bilateral S&T Partnership with the Russian Federation (BILAT-RUS)

Framework: FP7 — Capacities
Programme: Activities of International Cooperation
Destination: Bilateral coordination for the enhancement and development of S&T Partnerships
Action type: Coordination and support actions
Countries involved: Germany,Russian Federation,France,Austria,Germany
Call:  (FP7-INCO-2007-2, 2007)
Start date: 2008-09-01
End date: 2012-08-31
Duration (months): 48.0
Total project cost (EUR): 597076.06
EU funding (EUR): 492888.76
Participants: 9
Project status: CLOSED

BILAT-RUS focuses on enhancing the bilateral S&T Partnership between Russia and the EU. The project aims at contributing to the implementation of the Common Space on Research between the EU and Russia. It will ensure coherence and coordination of various activities under the umbrella of the EU-Russian S&T agreement and will contribute to a stronger coordination of bilateral activities with Russia at EU and Member State level. The major objectives of BILAT-RUS are: • to facilitate coherent information dissemination and awareness raising on EU-Russian cooperation (database on S&T research institutes, case studies on good cooperation practice, web-portal, partner search tool, information events); • to contribute to the optimisation of the framework and the instruments for enhanced future EU-Russian cooperation (inventory of existing instruments and regulations, examples of good cooperation practice, options for optimising the common legal and organisational frame, suggestions for practical and efficient joint funding mechanisms); • to create a knowledge base for emerging horizontal issues of cooperation (mobility, S&T infrastructure and innovation); • to meet the needs of joint thematic EU-Russian Working Groups on S&T cooperation (Health, Food/Agriculture/Biotechnology, Nanotechnology, Energy); • to exploit the potential of Russian Mirror Technology Platforms through linking them with their European counterparts. The project proposal for BILAT-RUS is built on joint EU-Russian interest and aims at mutual benefit. Synergies will be established with other bilateral or bi-regional EU-Russian projects from FP6 and FP7 (such as SCOPE-EAST and the upcoming IncoNet EECA targeting Eastern Europe and Central Asia), bilateral S&T agreements and other initiatives between the EU Member States and Russia. The consortium consists of ten partners (five of them from Russia) with in-depth experience of EU-Russian cooperation in S&T. The Russian NCPs are associated partners.

Keywords: science and technology,research,eu-russian cooperation,russia,bilateral cooperation
Advanced affinity tools and technologies for high throughput studies of the human proteome (AFFINITYPROTEOME)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Germany,Germany,Germany,Switzerland,United Kingdom,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2012-02-29
Duration (months): 36.0
Total project cost (EUR): 4059348.4
EU funding (EUR): 2988045.0
Participants: 10
Project status: CLOSED

High specificity affinity reagents (‘binders’) are essential probes for proteome research, enabling the detection and localisation of multiple proteins in tissues and fluids in health and disease, through the application of binder-based technologies (affinity proteomics). This proposal links the high throughput production of quality-controlled, recombinant binding molecules of different types (antibody fragments, engineered scaffolds, aptamers) with advanced applications (capture microarrays, multidimensional fluorescence imaging, single molecule detection, intracellular knockdown) in the analysis of human proteome targets. The partners are five established SMEs and five leading academic groups, each with a reputation for innovation, engaged in binder production and characterisation or protein detection technologies. The project will aim to resolve bottlenecks in high throughput binder production and application technologies, including cost, throughput, automation and quality. The linkage of production, quality control and applications will be exemplified by targeting kinases and other proteins involved in the TGF-beta and MAP kinase signal transduction pathways, implicated in many diseases and where the availability of high quality binding reagents is particularly needed and drug development is actively evolving. As well as potential products, it will provide the SMEs with opportunities to exemplify and improve their technologies for future exploitation in proteomics, diagnostics and therapeutics.

Keywords: human proteomics,affinity binding reagent,high throughput,antibody,microarray
Characterization and modelling of dietary effects mediated by gut microbiota on lipid metabolism (ETHERPATHS)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Fork to farm: Food (including seafood), health and well being
Action type: Collaborative project
Countries involved: Finland,Spain,Sweden,United Kingdom,Italy,Sweden,Switzerland,Russian Federation,Spain,United Kingdom
Call:  (FP7-KBBE-2007-2A, 2007)
Start date: 2009-01-01
End date: 2013-06-30
Duration (months): 54.0
Total project cost (EUR): 8292138.6
EU funding (EUR): 5946626.0
Participants: 10
Project status: CLOSED

Dysregulation of lipid homeostasis is related to multiple major global healthcare problems today, including aging, diabetes and cardiovascular disease. It has already been shown that nutritional modulation of lipid homeostasis via direct supplementation, e.g., n-3 fatty acids, or via indirect mechanisms, e.g., dietary polyphenols, has beneficial effects on human health. There is growing evidence that ether phospholipids such as plasmalogens play a central role in mediating the beneficial effects, but the underlying mechanisms are not understood. ETHERPATHS will develop systems biology tools that will facilitate studies of dietary interventions aiming to modulate lipid homeostasis. Specifically, we will develop (1) models that enable studies of gut microbiota and its effect on host cell metabolism, (2) dynamic models of systemic lipid metabolism, and (3) pathway reconstruction methods to study tissue-specific effects of dietary interventions. All models will be optimized in the context of studies of dietary interventions and will be integrated into a sophisticated software platform. In silico strategies will be complemented by multiple experimental approaches, including (1) dietary interventions involving n-3 fatty acids and polyphenols, combined with tracer studies in vitro and in vivo (2) in vitro colon model (3) in vivo germ-free and conventional models of altered lipid metabolism, specifically of plasmalogen deficiency. ETHERPATHS includes academic and industrial partners with combined unique expertise in information technology, bioinformatics, metabolic and physiological modelling, systems engineering, biochemistry, microbiology, lipid metabolism, metabolomics, obesity and metabolic syndrome, and clinical nutrition. We expect the ETHERPATHS tools to be broadly applied in nutrition research, and anticipate that the novel findings generated within the project will be applied for development of new food products for better health.

Keywords: systems biology,lipidomics,metabolomics,bioinformatics,gut microflora,plasmalogens,pathway reconstruction
Improving nutrient efficiency in major European food, feed and biofuel crops to reduce the negative environmental impact of crop production (NUE-CROPS)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Sustainable production and management of biological resources from land, forest, and aquatic environment
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Germany,Bulgaria,Denmark,Switzerland,Germany,United States,Germany,United Kingdom,Türkiye,Denmark,United Kingdom,China,Netherlands
Call:  (FP7-KBBE-2007-2A, 2007)
Start date: 2009-05-01
End date: 2014-04-30
Duration (months): 60.0
Total project cost (EUR): 9597834.81
EU funding (EUR): 5999998.0
Participants: 15
Project status: CLOSED

The MAIN AIM of the proposed integrating project NUE-CROPS is to develop knowledge, models and tools required to (a) breed/select NUTRIENT USE EFFICIENT (NUE) CROPS and (b) integrate NUE-crops with AGRONOMIC INNOVATIONS to significantly reduce fertiliser use and associated negative environmental impacts of crop production, while maintaining or improving crop yield and quality. The consortium includes 10 academic centres of excellence and 3 large breeding companies in 6 EU member states, China (an ICPC region) and the USA. The strategic CONCEPTS/OBJECTIVES of NUE-CROPS are to support the: 1. DEVELOPMENT OF NUE-VARIETIES of 4 MAJOR EUROPEAN CROPS (wheat, oilseed rape, potato, maize) for different MACROCLIMATIC REGIONS. This will be based on (a) classical QTL identification methods, (b) association genetics approaches, (c) gene expression profiling (and where appropriate proteomic, metabolomic analyses and/or analytical transformation analyses) and (d) whole plant physiological studies. R&D activities will focus on the 4 major crops species, but deliverables from studies with model plants/crops (Arabidopsis, Brassica rapa, barley) will be used as “genetic bridges” for the genetically complex crops wheat and oilseed rape. 2. INTEGRATION of NUE-CROPS with INNOVATIVE MANAGEMENT approaches (e.g. improved fertilisation regimes, rotational designs, winter cover crop use and, tillage systems). This will be based on: (a) field experiments to evaluate the impact of NUE crops under contrasting agronomic scenarios and (b) the construction/validation of models/algorithms for nutrient budgeting/precision farming systems 3. To ESTABLISH an EFFICIENT TRAINING and DISSEMINATION programme aimed at rapid exploitation and application of project deliverables in commercial crop production.

Keywords: nutrient use efficiency,fertiliser use,nitrogen,phosphorus,crop breeding,marker assisted selection,association genetics,genomics,proteomics,metabolomics,crop agronomy.
Novel integrated strategies for worldwide mycotoxin reduction in the food and feed chains (MYCORED)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Fork to farm: Food (including seafood), health and well being
Action type: Collaborative project
Countries involved: Italy,United Kingdom,Austria,Denmark,Germany,Netherlands,France,Netherlands,Türkiye,Russian Federation,Egypt,Nigeria,Mexico,Argentina,Spain,South Africa,Italy,Hungary,Austria,Spain,Belgium
Call:  (FP7-KBBE-2007-2A, 2007)
Start date: 2009-04-01
End date: 2013-09-30
Duration (months): 54.0
Total project cost (EUR): 7372847.33
EU funding (EUR): 5769956.0
Participants: 26
Project status: CLOSED

MYCORED aims at developing strategic solutions to reduce contamination by mycotoxins of major concern in economically important food and feed chains. The following toxins and commodities are especially considered in the project: aflatoxins, trichothecenes, zearalenone, fumonisins in wheat/maize food and feed chains; ochratoxin A in the grape-wine and wheat chains; and aflatoxins in the dried fruit chain. Novel methodologies, efficient handling procedures and information, dissemination and educational strategies are considered in a context of multidisciplinary integration of know-how and technology to reduce mycotoxins exposure worldwide. Five work-packages (WPs) will develop novel solution driven strategies to reduce both pre-and post-harvest contamination in feed and food chains. They involve: i) optimization of plant resistance and fungicide use; ii) biocontrol to reduce toxigenic fungi in cropping systems, iii) predictive modelling and optimise logistics; iv) novel post-harvest and storage practices and v) application of new food processing technologies. Two horizontal WPs will develop enabling methodologies for i) advanced diagnostics and quantitative detection of toxigenic fungi and ii) rapid and multi-toxin detection of mycotoxins and relevant biomarkers. The project will significantly build on the outcome of several European projects (through most coordinators/partners of FP5 and FP6) on mycotoxins by supporting, stimulating and facilitating education and cooperation with countries having major mycotoxin concerns related to (international) trade and human health. The direct involvement of ICPC countries (Argentina, Egypt, Russia, South Africa, Turkey) and international organizations (CIMMYT,IITA) together with strong alliances with major research institutions in the USA (3 USDA Centers/5 Universities), Australia, Malaysia will strengthen the project through sharing experiences and resources from several past/ongoing mycotoxin projects in a global context.

Keywords: mycotoxins,food/feed chain,safety,resistance,biocontrol,modelling,detection,information
CONtrol of COmmunity-acquired MRSA: Rationale and Development of counteractions (CONCORD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,France,Portugal,United Kingdom,Poland,Denmark,Netherlands,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3937759.6
EU funding (EUR): 2994192.0
Participants: 9
Project status: CLOSED

Until recently, methicillin-resistant Staphylococcus aureus (MRSA) were confined to hospitals (HA-MRSA). However, community- and farm-associated MRSA (CA-and FA-MRSA) has developed as an important cause of infections. No strategies exist to combat these MRSA. CONCORD is aimed at explaining the ecological success in the community and the farm environment of CA- and FA-MRSA in contrast to HA-MRSA in order to facilitate the rationale and development of effective strategies against CA- and FA-MRSA. Epidemiology of CA-MRSA is complex and incomplete. To obtain both a more complete description of the epidemiology of CA-MRSA and recent isolates small scale surveillance will be performed among patients in the 20 most populous EU countries, pig farms in major pig exporting countries and important veal calve raising countries. Genomics data for CA-MRSA are limited and non-existent for FA-MRSA. Successful adaptation of MRSA to a new environment supposes either the acquisition of novel properties or the differential expression of genes already present. Only 2 CA-MRSA have been fully sequenced and the UMCU has sequenced a FA-MRSA. Whole genome sequencing, comparative genome hybridization and transcriptomics will be used to understand the genetic adaptations of MRSA in the community. The contribution of putative virulence factors to pathogenicity will be studied by knock-outs and complemented strains of these knock-outs. The strains will be tested in in vitro and ex vivo models to establish their physiological role. Mathematical modelling is an important tool to manage infection control. A few models exist that evaluate measures to reduce transmission of HA-MRSA or CA-MRSA in jails. No models are available for FA-MRSA. Modelling will provide both fundamental insights on MRSA epidemiology as well as specific recommendations or testable hypotheses for human and veterinary clinical practice. The potential of intervention strategies to combat CA- and FA-MRSA will be determined.

Keywords: community-acquired mrsa,explaining ecological success,mathematical modelling,intervention strategies
MOROCCO TO ERA (M2ERA)

Framework: FP7 — Capacities
Programme: Activities of International Cooperation
Destination: Bilateral coordination for the enhancement and development of S&T Partnerships
Action type: Coordination and support actions
Countries involved: Morocco,Italy,France
Call:  (FP7-INCO-2007-2, 2007)
Start date: 2008-12-01
End date: 2012-05-31
Duration (months): 42.0
Total project cost (EUR): 577284.0
EU funding (EUR): 500000.0
Participants: 6
Project status: CLOSED

The M2ERA proposal builds on the success of the implementation of previous initiatives supported by the EC to increase awareness of research and collaboration activities between Morocco and the ERA. Furthermore, the present project will reinforce and complement the SSA’s projects in which the Moroccan department of research has participated (Euromedanet, Food-N-CO, Idea-Ist, Promedaccess, MED7. The ERA-MED and MIRA project actually in progress will benefit from the synergies driven of sharing similar objectives. The M2ERA objective is to support, on a coordinated and efficient manner, the participation and involvement of the Moroccan R&D stakeholders in the ERA activities, mainly through the implementation of a sustainable structure for FP’s promotion as thematic NCP’s, information and awareness activities, partnership promotion by organisation and attendance of high-level events and improving the Moroccan environment to motivate researchers to involve European research projects. The project includes a qualitative and qualitative assessment of the S&T Moroccan EU cooperation in order to identify motivations, obstacles, and impact of this cooperation. The support of political dialogue in this project will help to identify priorities of collaboration, enhance the quality, quantity and visibility of future actions and set Links between existing S&T programs.

Keywords: morocco,s&t cooperation,partnership,political,dialogue,ncp,7fp
Persisting Transgenesis (PERSIST)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,France,Germany,Germany,Switzerland,United Kingdom,Germany,Germany,Netherlands,Sweden,Germany,Belgium,Germany,France,Germany,France,Spain,Germany,Belgium,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2013-06-30
Duration (months): 54.0
Total project cost (EUR): 14731788.72
EU funding (EUR): 11181411.0
Participants: 29
Project status: CLOSED

For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize on recent discoveries in gene expression control to develop radical solutions to the problem of precisely controlling the fate and expression of exogenous genetic information in gene therapy with applications in these and other deadly diseases. Our proposal combines 20 of Europe’s outstanding experts from 8 countries in the field of genetic engineering for persisting gene expression. Partners have pioneered the use of Zinc Finger Nucleases, engineered recombinases and transposases for gene targeting, synthetic promoters, epigenetic switches and micro-RNA for regulating gene expression, developed state-of-the-art gene delivery platforms based on lentiviral, AAV and gutless adenoviral vectors, conducted front-line clinical trials, and productively collaborated in previous FP projects. PERSIST includes 16 work packages of which 6 focus on vector innovations (part A: emerging technologies), 6 on applications & evaluation (part B), 1 on process development and the remaining 2 on training/dissemination and project management including IPR issues. Targeting deadly diseases, such as inherited immunodeficiencies, storage disorders and haemophilias, PERSIST is in line with the Strategic Research Agenda (SRA) of the Innovative Medicines Initiative (IMI) and will result in: faster discovery and development of better medicines; more attractive professional environment for scientists; better European expertise and know-how to attract biomedical R&D investment in Europe; and a stronger competitive advantage for SMEs, spin-offs and start-ups to enhance Europe’s economy.

Keywords: gene therapy,gene targeting,lentiviral vectors,inherited diseases,immunodeficiencies,hemophilias,storage disorders,site-specific gene editing,gutless adenoviral vector,clinical applications